News

UroToday3d
Bayer to Unveil Latest NUBEQA® (darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting
• Ultra-low PSA Response (<0.02 ng/mL) with Darolutamide Plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes Interactive Poster Session: IP26-07; April 29, 9:30-11:30 a.m. PDT ...
UroToday4d
Performance Large Language Models in Guiding Bladder Cancer Management - Expert Commentary
Bladder cancer (BLCA) management presents complex clinical challenges requiring deep knowledge of current guidelines and clinical expertise. A recent study by Li et al. evaluated the performance of ...
UroToday4d
Shifting Tides: A Survey Analysis of Urologists' Evolving Attitudes Toward Focal Therapy for Prostate Cancer - Beyond the Abstract
Focal therapy (FT) has quickly emerged over the last few decades as a prostate cancer (CaP) treatment option due to the growing research indicating more favorable side effects compared to radical ...
UroToday4d
CRISPR Screening Identifies Regulators of Enhancer-Mediated Androgen Receptor Transcription in Advanced Prostate Cancer - Beyond the Abstract
One of the clearest examples of an acquired somatic mutation is androgen receptor (AR) amplifications in prostate cancers that have been treated with androgen deprivation therapy (ADT). 1,2 ...
UroToday4d
Single-Dose Radiation Therapy for Localized Prostate Cancer: Where Does the Evidence Lead?
Prostate cancer (PCa) remains the most prevalent cancer among men and the second leading cause of cancer-related deaths worldwide. Early diagnosis is crucial as it opens up various treatment options ...
UroToday4d
Analytical Validation of MyProstateScore 2.0.
Background/Objectives: Prostate cancer (PCa) is a leading cause of cancer-related deaths among men, with early detection playing a crucial role in improving outcomes. MyProstateScore 2.0 (MPS2), a ...
UroToday4d
Clinical Outcomes and Genomic Alterations in Gleason Score 10 Prostate Cancer.
Background: Gleason score (GS) 10 prostate cancer (PC) is a highly aggressive localized disease. Despite advances in treating high-risk PC, the clinical outcomes and molecular underpinnings of GS 10 ...
UroToday4d
Investigation of whether renal tumours with caval thrombi induce particular risks: a multicentre study (UroCCR-174 CAVORISK).
To compare outcomes of nephrectomy for left-sided (n = 70) vs right-sided (n = 118) renal tumours with caval thrombi. In this retrospective analysis (June 2008-February 2023), we evaluated ...
UroToday4d
Data set for reporting paediatric renal tumours: recommendations from the international collaboration on cancer reporting (ICCR).
Tumours arising within the developing kidney of children vary widely in their histological appearance and outcome; optimal therapy requires accurate classification and staging. The two major ...
UroToday4d
Adverse In-Hospital Outcomes Following Robot-Assisted vs. Open Radical Prostatectomy in Quadragenarians.
Background/Objectives: Adverse in-hospital outcomes at radical prostatectomy have not been specifically addressed in young patients aged 40-49 years (quadragenarians). Additionally, no comparison ...
UroToday4d
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...